奥贝胆酸治疗肝硬化脂肪肝效果如何？

(Obeticholic acid) is a new liver disease drug developed by Intercept, an American biopharmaceutical company. Obeticholic acid has received accelerated approval from the FDA and is used in combination with ursodeoxycholic acid (UDCA) for adult patients with primary biliary cholangitis (primary biliary cirrhosis, PBC) who have insufficient response to UDCA. Nonalcoholic steatohepatitis (NASH) is a severe, progressive nonalcoholic fatty liver disease (NAFLD) caused by fat accumulation, often accompanied by liver inflammation, hepatocellular scarring, and liver damage, leading to liver fibrosis and cirrhosis, ultimately leading to liver cancer or liver failure. Obeticholic acid is a farnesoid X receptor agonist, which indirectly inhibits the gene expression of cytochrome 7A1 (CYP7A1) by activating the farnesoid X receptor. Thus achieving therapeutic effect.

Ursodeoxycholic acid (UDCA) is the only drug approved by the US FDA for the treatment of PBC. However, more than 40% of patients do not respond adequately to UDCA or are intolerant to UDCA. The clinical advantage of obeticholic acid is that it can significantly improve the biochemical indicators of PBC patients who have poor response or intolerance to UDCA treatment, delay disease progression, and improve survival rates.

How effective is the treatment of cirrhosis and fatty liver? In large-scale clinical trials, obeticholic acid successfully controlled or even reversed pathological characteristics such as liver inflammation, hepatic steatosis, and liver fibrosis. What is even more exciting is that its efficacy is particularly significant in high-risk groups, such as those with concurrent diabetes, excessive transaminases, and those who are overweight. Obeticholic acid can not only inhibit the progression of fatty liver, but also reverse the damage of fatty liver in some patients, restore the normal cell tissue morphology of the mildly or even moderately diseased liver, and likely inhibit cirrhosis!